Skip to main content
Announcements

Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business

November 4, 2024

Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.

The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).

連絡先

Belke, Daniel J.
パートナー
Hofheimer, Joshua T.
パートナー
Grau, Lauren G.
パートナー
Petkov, Antoinette R.
アソシエイト
Glavota, Sabrina K.
Managing Associate

得意分野

Suggested News & Insights

Global ESG and Sustainability Update: Reporting & Due Diligence Developments and Compliance StrategiesTuesday, May 19, 2026
Events
Sidley Represents Nourish in US$100 Million Series C FinancingMay 19, 2026
Announcements
When “The Devil Made Me Do It” Is Not a Defense: Lessons in AI Governance and Organizational Oversight from an SDNY DecisionMay 18, 2026
Enhanced Scrutiny
Sidley Advises Big 12 Conference on Partnership With RedBird Capital PartnersMay 15, 2026
Announcements
Sidley Represents J.S. Held in Acquisitions of Clark Seif Clark and CMMMay 13, 2026
Announcements
Texas Corporate Litigation Reforms Take Hold: Federal Court Enforces Texas’s 3% Ownership Requirement for Derivative ClaimsMay 12, 2026
Enhanced Scrutiny